JPMorgan Funds - Thematics - Genetic Therapies Fund C (dist) GBP

Category Sector Equity Biotechnology


star-filledstar-filled
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price

£78.96

arrow-down£-1.17 (-1.46%)

Fund Code

JMGTI

BMXMZ45

LU2314628723

Prices updated as at 13 Nov 2026
|
Prices in GBP

Investment objective
The fund seeks to achieve a return by investing in companies with exposure to the theme of genetic therapies, globally.

Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.

Fund statusOpen
Fund typeSICAV
Fund managerYazann Romahi, Aijaz Hussain
84.72
65.16
Fund comparative indexMSCI ACWI NR USD
-
-
0.56
0.03
0.00
Sector Equity Biotechnology
No
Fund providerJPMorgan Asset Management (Europe) S.à r.l.
Share class launch date17 Mar 2021
£290.39m
-
-
-
Annually
Please note that some funds may have small additional incidental charges that are not shown here. Where these charges do exist they are included within the variable ongoing costs in the Pre-sale Illustration.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.